CN113509399A - 一种壳糖胺HCl脂质体微胶囊及其制备方法与祛黑色素应用 - Google Patents
一种壳糖胺HCl脂质体微胶囊及其制备方法与祛黑色素应用 Download PDFInfo
- Publication number
- CN113509399A CN113509399A CN202110688558.3A CN202110688558A CN113509399A CN 113509399 A CN113509399 A CN 113509399A CN 202110688558 A CN202110688558 A CN 202110688558A CN 113509399 A CN113509399 A CN 113509399A
- Authority
- CN
- China
- Prior art keywords
- chitosamine
- hcl
- phase
- liposome
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QKPLRMLTKYXDST-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-NSEZLWDYSA-N 0.000 title claims abstract description 48
- 239000002502 liposome Substances 0.000 title claims abstract description 42
- 239000003094 microcapsule Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 title abstract description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940107161 cholesterol Drugs 0.000 claims abstract description 9
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 8
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 239000000725 suspension Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000007709 nanocrystallization Methods 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 210000002752 melanocyte Anatomy 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种壳糖胺HCl脂质体微胶囊及其制备方法与祛黑色素应用。壳糖胺HCl脂质体微胶囊,以壳糖胺HCl为有效成分,壳糖胺HCl包裹于脂质体中,形成混悬液;按照重量百分比,壳糖胺HCl 0.01‑0.20%,脂质体0.05‑1%,余量为水溶液。所述脂质体由大豆卵磷脂、胆固醇和维生素E溶于无水酒精中制成。本发明所制备的壳糖胺HCl脂质体微胶囊的纳米化分子量小,渗透力强,易吸收;另外其涂覆到肌肤上,可以分解黑色素细胞,从而起到祛黑色素的作用,可应用于化妆品、药品中。
Description
技术领域
本发明涉及化妆品技术领域,具体地说,涉及一种一种壳糖胺 HCl脂质体微胶囊及其制备方法与祛黑色素应用。
背景技术
壳糖胺 HCl,英文名(INCI):GLUCOSAMINE HCL,成分别名:氨基葡糖HCL。现有壳糖胺 HCl在化妆品、护肤品里主要作用是抗静电和作为头发调理剂,风险系数为1,比较安全,可以放心使用,对于孕妇一般没有影响,壳糖胺 HCl没有致痘性。
脂质体一般是由磷脂双分子层构成的亲水性囊泡,具有提高被包封药物的稳定性、促进药物透皮吸收、延长药物的作用时间、对局部疾病部位的靶向作用、降低药物毒副作用等特点。因此,脂质体作为药物载体已广泛应用于药物制剂及化妆品工艺配方中。
然而壳糖胺 HCl由于结构的特殊性,制成脂质体有一定的难度,现有技术未有关于壳糖胺 HCl脂质体的记载。
发明内容
本发明的目的在于克服现有技术的不足,提供一种壳糖胺 HCl脂质体微胶囊及其制备方法与祛黑色素应用
为了实现上述目的,本发明采用如下技术方案:
一种壳糖胺 HCl脂质体微胶囊,以壳糖胺 HCl为有效成分,壳糖胺 HCl包裹于脂质体中,形成混悬液;按照重量百分比,壳糖胺 HCl 0.01-0.20%,脂质体0.05-1%,余量为水溶液。
作为优选的,在上述的壳糖胺 HCl脂质体微胶囊中,所述脂质体由大豆卵磷脂、胆固醇和维生素E溶于无水酒精中制成。
上述壳糖胺 HCl脂质体微胶囊的制备方法,包括如下步骤:
(1)将大豆卵磷脂、胆固醇和维生素E溶于无水酒精中,搅拌至完全溶解制成脂质体,作为I相;壳糖胺 HCl作为II相;磷酸氢二钠、磷酸二氢钠、EDTA 二钠和HL-10溶于灭菌水中,作为III相;
(2)将II相壳糖胺 HCl置于高压微射流均质机和灭菌水进行纳米化;
(3)将I相置于圆形瓶中,开启设备温度38-40℃,搅拌50r/min,真空-0.1mpa;搅拌蒸发酒精,至瓶中无气泡冒出后停止;
(4)将部分III相置于烧杯内搅拌溶解均匀,加入I相和II相,摇晃至I相、II相完全溶解;
(5)将步骤(4)的混合均匀液体倒入烧杯中均质;
(6)将步骤(5)的混合液体倒入圆形瓶中,开启设备温度38-40℃,搅拌50r/min,真空-0.1mpa,至液体内无气泡;
(7)将步骤(6)的混合液体倒入烧杯中,再将剩余III相液体全部加入,磁力搅拌,均质;
(8)将步骤(7)的混合液体再次倒入高压微射流均质机中,开启设备至液体内无气泡进行纳米化处理即可得到壳糖胺 HCl脂质体微胶囊
与现有技术相比,本发明具有如下有益效果:本发明所制备的壳糖胺 HCl脂质体微胶囊的纳米化分子量小,渗透力强,易吸收;另外其涂覆到肌肤上,可以分解黑色素细胞,从而起到祛黑色素美白的作用,可应用于化妆品、药品中。
附图说明
图1为皮肤黑色素原图;
图2用脂质体包裹壳糖胺 HCl作用2d后黑色素细胞的分解图;
图3为用脂质体包裹壳糖胺 HCl作用5d后黑色素细胞的分解图;
图4为用脂质体包裹壳糖胺 HCl作用7d后黑色素细胞的分解图。
具体实施方式
实施例1:壳糖胺 HCl脂质体微胶囊的制备:
(1)将大豆卵磷脂、胆固醇和维生素E溶于无水酒精中,搅拌至完全溶解制成脂质体,作为I相;取3g壳糖胺 HCl作为II相;磷酸氢二钠、磷酸二氢钠、EDTA 二钠和HL-10溶于灭菌水中,作为III相;
I相的配方是:
大豆卵磷脂 15g
胆固醇 2.85g
无水酒精 200ml
维生素E 1.3g。
III相的配方是:
磷酸氢二钠 14.1g
磷酸二氢钠 6.65g
EDTA 二钠 2g
灭菌水 2000g
HL-10 16g。
(2)将II相壳糖胺 HCl置于高压微射流均质机和灭菌水进行纳米化;
(3)将I相置于圆形瓶中,开启设备温度38℃,搅拌50r/min,真空-0.1mpa;搅拌蒸发酒精,至瓶中无气泡冒出后停止;
(4)将部分III相置于烧杯内搅拌溶解均匀,加入I相和II相,摇晃至I相、II相完全溶解;
(5)将步骤(4)的混合均匀液体倒入烧杯中均质;
(6)将步骤(5)的混合液体倒入圆形瓶中,开启设备温度38℃,搅拌50r/min,真空-0.1mpa,至液体内无气泡;
(7)将步骤(6)的混合液体倒入烧杯中,再将剩余III相液体全部加入,磁力搅拌,均质;
(8)将步骤(7)的混合液体再次倒入高压微射流均质机中,开启设备至液体内无气泡进行纳米化处理即可得到壳糖胺 HCl脂质体微胶囊。
实施例2:壳糖胺 HCl脂质体微胶囊的制备:
(1)将大豆卵磷脂、胆固醇和维生素E溶于无水酒精中,搅拌至完全溶解制成脂质体,作为I相;取3g壳糖胺 HCl作为II相;磷酸氢二钠、磷酸二氢钠、EDTA 二钠和HL-10溶于灭菌水中,作为III相;
I相的配方是:
大豆卵磷脂 17g
胆固醇 2.95g
无水酒精 200ml
维生素E 2g。
III相的配方是:
磷酸氢二钠 14.8g
磷酸二氢钠 7.65g
EDTA 二钠 3g
灭菌水 2000g
HL-10 14g。
(2)将II相壳糖胺 HCl置于高压微射流均质机和灭菌水进行纳米化;
(3)将I相置于圆形瓶中,开启设备温度40℃,搅拌50r/min,真空-0.1mpa;搅拌蒸发酒精,至瓶中无气泡冒出后停止;
(4)将部分III相置于烧杯内搅拌溶解均匀,加入I相和II相,摇晃至I相、II相完全溶解;
(5)将步骤(4)的混合均匀液体倒入烧杯中均质;
(6)将步骤(5)的混合液体倒入圆形瓶中,开启设备温度40℃,搅拌50r/min,真空-0.1mpa,至液体内无气泡;
(7)将步骤(6)的混合液体倒入烧杯中,再将剩余III相液体全部加入,磁力搅拌,均质;
(8)将步骤(7)的混合液体再次倒入高压微射流均质机中,开启设备至液体内无气泡进行纳米化处理即可得到壳糖胺 HCl脂质体微胶囊。
实施例3 功效实验
将实施例1所得壳糖胺 HCl脂质体微胶囊应用于化妆品中,涂覆到肌肤表面,图1为未涂覆壳糖胺 HCl脂质体微胶囊的皮肤黑色素原图;从图2-4可知,涂覆了壳糖胺 HCl脂质体微胶囊的皮肤黑色素细胞,随着时间的推移,黑色素细胞有明显的分解作用。
Claims (4)
1.一种壳糖胺 HCl脂质体微胶囊,其特征在于,以壳糖胺 HCl为有效成分,壳糖胺 HCl包裹于脂质体中,形成混悬液;按照重量百分比,壳糖胺 HCl 0.01-0.20%,脂质体0.05-1%,余量为水溶液。
2.如权利要求1所述的壳糖胺 HCl脂质体微胶囊,其特征在于,所述脂质体由大豆卵磷脂、胆固醇和维生素E溶于无水酒精中制成。
3.权利要求1所述壳糖胺 HCl脂质体微胶囊的制备方法,其特征在于包括如下步骤:
(1)将大豆卵磷脂、胆固醇和维生素E溶于无水酒精中,搅拌至完全溶解制成脂质体,作为I相;壳糖胺 HCl作为II相;磷酸氢二钠、磷酸二氢钠、EDTA 二钠和HL-10溶于灭菌水中,作为III相;
(2)将II相壳糖胺 HCl置于高压微射流均质机和灭菌水进行纳米化;
(3)将I相置于圆形瓶中,开启设备温度38-40℃,搅拌50r/min,真空-0.1mpa;搅拌蒸发酒精,至瓶中无气泡冒出后停止;
(4)将部分III相置于烧杯内搅拌溶解均匀,加入I相和II相,摇晃至I相、II相完全溶解;
(5)将步骤(4)的混合均匀液体倒入烧杯中均质;
(6)将步骤(5)的混合液体倒入圆形瓶中,开启设备温度38-40℃,搅拌50r/min,真空-0.1mpa,至液体内无气泡;
(7)将步骤(6)的混合液体倒入烧杯中,再将剩余III相液体全部加入,磁力搅拌,均质;
(8)将步骤(7)的混合液体再次倒入高压微射流均质机中,开启设备至液体内无气泡进行纳米化处理即可得到壳糖胺 HCl脂质体微胶囊。
4.权利要求1所述壳糖胺 HCl脂质体微胶囊在制备祛黑色素化妆品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110688558.3A CN113509399A (zh) | 2021-06-22 | 2021-06-22 | 一种壳糖胺HCl脂质体微胶囊及其制备方法与祛黑色素应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110688558.3A CN113509399A (zh) | 2021-06-22 | 2021-06-22 | 一种壳糖胺HCl脂质体微胶囊及其制备方法与祛黑色素应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113509399A true CN113509399A (zh) | 2021-10-19 |
Family
ID=78065758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110688558.3A Pending CN113509399A (zh) | 2021-06-22 | 2021-06-22 | 一种壳糖胺HCl脂质体微胶囊及其制备方法与祛黑色素应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113509399A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060018851A1 (en) * | 2004-06-28 | 2006-01-26 | Procyte Corporation | Methods and compositions for preventing and treating hyperpigmentation of skin |
CN1901920A (zh) * | 2003-11-21 | 2007-01-24 | 雀巢技术公司 | 含有氨基葡糖的食物组合物 |
CN105581978A (zh) * | 2014-10-20 | 2016-05-18 | 湖南师范大学 | 氨基葡萄糖衍生物阳离子脂质体纳米颗粒的制备方法 |
CN110652658A (zh) * | 2018-06-28 | 2020-01-07 | 强生消费者公司 | 使用光和葡糖胺盐酸盐处理皮肤病症的组合物和方法 |
CN112754949A (zh) * | 2021-01-26 | 2021-05-07 | 烟台仙瑟商贸有限公司 | 一种缓释型亮肤精华组合物及其制备方法 |
-
2021
- 2021-06-22 CN CN202110688558.3A patent/CN113509399A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1901920A (zh) * | 2003-11-21 | 2007-01-24 | 雀巢技术公司 | 含有氨基葡糖的食物组合物 |
US20060018851A1 (en) * | 2004-06-28 | 2006-01-26 | Procyte Corporation | Methods and compositions for preventing and treating hyperpigmentation of skin |
CN105581978A (zh) * | 2014-10-20 | 2016-05-18 | 湖南师范大学 | 氨基葡萄糖衍生物阳离子脂质体纳米颗粒的制备方法 |
CN110652658A (zh) * | 2018-06-28 | 2020-01-07 | 强生消费者公司 | 使用光和葡糖胺盐酸盐处理皮肤病症的组合物和方法 |
CN112754949A (zh) * | 2021-01-26 | 2021-05-07 | 烟台仙瑟商贸有限公司 | 一种缓释型亮肤精华组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
裘炳毅、高志红: "《现代化妆品科学与技术 中》", 31 March 2016, 中国轻工业出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101810160B1 (ko) | 생리활성물질이 봉입된 에토좀 제조 방법, 에토좀 조성물 및 에토좀 조성물을 포함하는 화장료 조성물 | |
DE102008034944B4 (de) | Mikroemulsion | |
US9849088B2 (en) | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof | |
CN109481321B (zh) | 一种美白祛斑的传明酸柔性脂质体及其制备方法和应用 | |
CN101904814A (zh) | 制备载药乳剂的方法 | |
JP2003533491A (ja) | 薬学的及び/又は美容的組成物 | |
Gupta et al. | Transfersomes: the ultra-deformable carrier system for non-invasive delivery of drug | |
PT1853303E (pt) | Composições estabilizadas para administração tópica, e métodos para a sua preparação | |
EP2672978A1 (en) | Permeation enhancers for topical formulations | |
US11801302B2 (en) | Formulations and uses thereof | |
KR20180131876A (ko) | 리포좀 기술을 이용한 안정화된 세라마이드 복합물 및 그 제조 방법 및 이를 함유하는 화장료 조성물 | |
Behtash et al. | New generation of fluconazole: a review on existing researches and technologies | |
CN102091038B (zh) | 艾地苯醌纳米脂质载体透皮吸收制剂及制备方法 | |
US20070042007A1 (en) | Topical composition for delivery of salicylate esters | |
US20240226060A1 (en) | Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof | |
CN113509399A (zh) | 一种壳糖胺HCl脂质体微胶囊及其制备方法与祛黑色素应用 | |
KR101761005B1 (ko) | 법제 유황을 포함하는 피부보습, 항염 및 면역 증강용 화장료 조성물 및 그 제조방법 | |
CN108403637A (zh) | 一种口腔喷雾制剂及其制备方法 | |
KR20020008598A (ko) | 리포좀 화장료 조성물 및 이를 함유하는 부직포 | |
CN113576937A (zh) | 一种熊果苷固体纳米脂质体的制备方法 | |
CA2877102C (en) | Topical formulations including lipid microcapsule delivery vehicles and their uses | |
KR101702482B1 (ko) | 나노리포좀이 형성되어 피부면역력, 살균력 및 흡수력이 향상된 화장료 조성물 및 그 제조방법 | |
RU2155604C2 (ru) | Лецитиновый органогель | |
JAIN et al. | Ketoconazole laden microemulsion based gel formulation against skin fungal infection | |
JP2003212751A (ja) | ゲル組成物および水中油(o/w)型組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211019 |
|
RJ01 | Rejection of invention patent application after publication |